Pfizer (PFE) Receivables - Other (2009 - 2023)

Pfizer (PFE) has 8 years of Receivables - Other data on file, last reported at $57.0 million in Q2 2023.

• Receivables - Other for Q2 2023 came in at $57.0 million, down 57.14% year-over-year; the trailing twelve-month figure through Apr 2023 was $57.0 million (down 57.14% YoY), and the FY2021 annual result was $53.0 million, down 86.78% from the prior year.
• Receivables - Other retreated to $57.0 million in Q2 2023 per PFE's latest filing, from $167.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $871.0 million in Q2 2021 and troughed at $53.0 million in Q4 2021.
• A 4-year average of $287.2 million and a median of $197.0 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2021 and 2022: Receivables - Other sank 86.78% in 2021, then slipped 15.23% in 2022.
• A 4-year view of Receivables - Other shows it stood at $401.0 million in 2020, then slumped by 86.78% to $53.0 million in 2021, then soared by 215.09% to $167.0 million in 2022, then tumbled by 65.87% to $57.0 million in 2023.
• Business Quant data shows PFE's Receivables - Other at $57.0 million in Q2 2023, $167.0 million in Q4 2022, and $272.0 million in Q3 2022.